AbbVie is presenting clinical and real-world data at the 2026 World Conference on Lung Cancer (WCLC).
The presentations feature investigational programs ABBV-1480, telisotuzumab adizutecan, and ABBV-706. These therapies target both non-small cell and small cell lung cancer.
This oncology showcase supports AbbVie's strategy to diversify revenue beyond its established immunology portfolio. The data provides investors with milestones to evaluate the company's progress in next-generation cancer therapies.